Meridian Bioscience (NAS: VIVO) reported earnings on April 25. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q2), Meridian Bioscience missed estimates on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged. GAAP earnings per share grew.
Margins expanded across the board.
Meridian Bioscience reported revenue of $47.3 million. The 10 analysts polled by S&P Capital IQ looked for revenue of $49.3 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.24. The 11 earnings estimates compiled by S&P Capital IQ forecast $0.24 per share. GAAP EPS of $0.24 for Q2 were 4.3% higher than the prior-year quarter's $0.23 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 65.0%, 230 basis points better than the prior-year quarter. Operating margin was 32.3%, 60 basis points better than the prior-year quarter. Net margin was 21.7%, 140 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $46.5 million. On the bottom line, the average EPS estimate is $0.22.
Next year's average estimate for revenue is $189.1 million. The average EPS estimate is $0.89.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 461 members out of 471 rating the stock outperform, and 10 members rating it underperform. Among 106 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 104 give Meridian Bioscience a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is hold, with an average price target of $21.00.
Looking for alternatives to Meridian Bioscience? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
Add Meridian Bioscience to My Watchlist.
The article Fool Checkup: Meridian Bioscience Earnings originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.